Clinical Trials
Search our team at AdventHealth Research Institute
-
rhPSMA-7.3(18F)-PET scan to detect prostate cancer in patients with early PSA recurrence.
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe research is being done at the Radiology Nuclear Medicine Department of AdventHealth Orlando and Celebration. Patients are instructed to drink water prior to administration of flotufolastat F-18 to...
-
NCT05987241
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer A032103
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThis study is being done to answer the following question: After having your bladder surgically removed after being diagnosed with bladder cancer, can we better identify which patients need an...
-
NCT06318273
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-969 in Adult Subjects With Metastatic Castration-Resistant Prostate Cancer
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: CelebrationThe purpose of this study is to see if the study drug is safe and tolerable.
This study will consist of 2 main phases: dose escalation (Part 1) and dose expansion (Part 2). In Part 1, multiple... -
NCT06305767
A Phase 2, Randomized, Double-blind Study of Adjuvant V940 (mRNA-4157) + Pembrolizumab (MK-3475) vs. Placebo + Pembrolizumab for High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC) Post-Radical Resection
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoTo compare V940 plus pembrolizumab to
placebo plus pembrolizumab with respect to DFS. Hypothesis (H1): V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS as assessed... -
NCT04510597
PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931)
This study is currently enrolling.Associated Conditions: GenitourinaryResearch Area: Clinical Cancer ResearchResearch Location: OrlandoPHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL) (Study SWOG 1931)